Mexico Hypoprothrombinemia Treatment Market Size & Outlook, 2026-2034


Mexico Hypoprothrombinemia Treatment Market Insights

  • Reed Intelligence analysis indicates that the Mexico Hypoprothrombinemia Treatment Market size, valued at USD 6.59 Billion in 2025, is expected to expand to USD 14.11 Billion by 2034.
  • The Mexico market is forecasted to expand at a CAGR of 8.87% spanning 2026–2034.
  • Plasma-Derived Products held the leading position among Treatment Type segments in 2025, based on market size.
  • Others is projected to post the fastest growth rate, sustaining its position as the most attractive Treatment Type segment during the forecast horizon.

Other Key Findings


  • Mexico accounted for 2.06% of the global Hypoprothrombinemia Treatment Market size in 2025.
  • By 2034, United States is expected to remain the top global market in terms of size.
  • Within LATAM, Brazil is forecasted to dominate the regional Hypoprothrombinemia Treatment Market size by 2034.
  • Chile will be the fastest-growing market in LATAM, projected to achieve USD 4.34 Billion by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 6.59 Billion
Market Size In 2034 USD 14.11 Billion
Largest segment Plasma-Derived Products
Units Revenue in USD Billion
CAGR 8.87% (2026-2034)
Segmnetation Covered
Treatment Type
  1. Plasma-Derived Products
  2. Recombinant Therapies
  3. Others
Application
  1. Congenital Hypoprothrombinemia
  2. Acquired Hypoprothrombinemia
End-Use
  1. Hospitals
  2. Specialty Clinics
  3. Home Care Settings
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports